[1]多力昆·木台力甫?阿布都赛米·艾尼 阿布都乃比·麦麦提艾力.青年女性患者心脏瓣膜的选择[J].心血管病学进展,2024,(6):489.[doi:10.16806/j.cnki.issn.1004-3934.202.06.003]
　Duolikun·Mutailifu,Abudusaimi·Aini,Abudunaibi·Maimaitiaili.Duolikun·Mutailifu1,Abudusaimi·Aini1,Abudunaibi·Maimaitiaili2[J].Advances in Cardiovascular Diseases,2024,(6):489.[doi:10.16806/j.cnki.issn.1004-3934.202.06.003]
点击复制

青年女性患者心脏瓣膜的选择()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年6期
页码:
489
栏目:
综述
出版日期:
2024-06-25

文章信息/Info

Title:
Duolikun·Mutailifu1,Abudusaimi·Aini1,Abudunaibi·Maimaitiaili2
作者:
多力昆·木台力甫1?阿布都赛米·艾尼1 阿布都乃比·麦麦提艾力2
(1.新疆医科大学第一附属医院,新疆 乌鲁木齐 830054;2.新疆医科大学第一附属医院心脏外科,新疆 乌鲁木齐 830054)
Author(s):
Duolikun·Mutailifu1; Abudusaimi·Aini1; Abudunaibi·Maimaitiaili2
(1.The First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,Xinjiang,China; 2. Department of Cardiac Surgery,The First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,Xinjiang,China)
关键词:
人工心脏瓣膜; 孕妇; 抗凝药物; 心脏瓣膜病
Keywords:
Heart valve prosthesis; Pregnant woman; Anticoagulants; Valvular heart disease
DOI:
10.16806/j.cnki.issn.1004-3934.202.06.003
摘要:
瓣膜置换术后的青年女性患者在围产期有较高的母婴不良事件发生率。机械瓣膜置换术后孕妇妊娠期不良事件发生率较高，主要与抗凝治疗和机械瓣膜本身的易血栓形成特性有关。由于生物瓣膜衰败，其长期的耐久性有限，生物瓣膜置换术后青年女性将面临再次手术可能，因此在这些年轻女性中选择生物瓣膜存在争议。现围绕机械瓣膜术后孕妇抗凝治疗、围产期的各种不良事件、新型瓣膜、新型换瓣技术等方面做一综述,为有生育需求的青年女性患者在瓣膜选择方面提供理论基础。
Abstract:
Women with prosthetic heart valves are associated with an increased risk of maternal or fetal/neonatal adverse events during perinatal period. Pregnant women with mechanical valves are associated with a higher risk of adverse events,primarily due to anticoagulant therapy and the inherent thrombogenic nature of mechanical valves. Young women with bioprosthetic valves will face reoperation due to bioprosthetic valve deterioration and its limited long-term durability,the choice for a biological prosthetic heart valve in these young women is not indisputable. In this article,we reviewed the anticoagulant management for pregnant women after mechanical valve replacement,various adverse events during pregnancy,new generation prosthetic valves, and new valve replacement techniques,which provides a theoretical basis for the choice of valve replacement for women with pregnancy wish

参考文献/References:

[1] Minhas AS,Rahman F,Gavin N,et al. Cardiovascular and obstetric delivery complications in pregnant women with valvular heart disease[J]. Am J Cardiol,2021,158:90-97.
[2] Vahanian A,Beyersdorf F,Praz F,et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J,2022,43(7):561-632.
[3] Regitz-Zagrosek V,Roos-Hesselink JW,Bauersachs J,et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy[J]. Eur Heart J,2018,39(34):3165-3241.
[4] Bartczak-Rutkowska A,Trojnarska O,Ciep?ucha A,et al. Maternal outcomes of pregnancy in women with mechanical heart valves prostheses—A single-center experience[J]. Kardiol Pol,2021,79(11):1262-1264.
[5] Malvindi PG,Luthra S,Olevano C,et al. Aortic valve replacement with biological prosthesis in patients aged 50-69 years[J]. Eur J Cardiothorac Surg,2021,59(5):1077-1086.
[6] Rodríguez-Caulo EA,Blanco-Herrera OR,Berastegui E,et al. Biological versus mechanical prostheses for aortic valve replacement[J]. J Thorac Cardiovasc Surg,2023,165(2):609-617.e7.
[7] Goldstone AB,Chiu P,Baiocchi M,et al. Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement[J]. N Engl J Med,2017,377(19):1847-1857.
[8] Jakobsen C,Larsen JB,Fuglsang J,et al. Mechanical heart valves,pregnancy,and bleeding:a systematic review and meta-analysis[J]. Semin Thromb Hemost,2022,49(5):542-552.
[9] Daughety MM,Zilberman-Rudenko J,Shatzel JJ,et al. Management of anticoagulation in pregnant women with mechanical heart valves[J]. Obstet Gynecol Surv,2020,75(3):190-198.
[10] Otto CM,Nishimura RA,Bonow RO,et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease:executive summary:a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation,2021,143(5):e35-e71.
[11] 中华医学会胸心血管外科分会瓣膜病外科学组. 心脏瓣膜外科人工瓣膜选择中国专家共识J]. 中华胸心血管外科杂志2022,38(3):138-145.
[12] 中华医学会胸心血管外科分会瓣膜病外科学组. 心脏瓣膜外科抗凝治疗中国专家共识J]. 中华胸心血管外科杂志2022,38(3):164-174.
[13] Lester W,Walker N,Bhatia K,et al. British Society for Haematology guideline for anticoagulant?management of pregnant individuals with mechanical heart valves[J]. Br J Haematol,2023,202(3):465-478.
[14] Zullino S,Clemenza S,Mecacci F,et al. Low molecular weight heparins(LMWH) and implications along pregnancy:a focus on the placenta[J]. Reprod Sci,2021,29(5):1414-1423.
[15] James AH,Sugrue R,Federspiel JJ. Novel antithrombotic agents in pregnancy anticoagulants and antiplatelet agents[J]. Clin Obstet Gynecol,2023,66(1):196-207.
[16] Lameijer H,van Slooten YJ,Jongbloed MRM,et al. Biological versus mechanical heart valve prosthesis during pregnancy in women with congenital heart disease[J]. Int J Cardiol,2018,268:106-112.
[17] Singab H,Sami G. Mitral valve bioprosthesis is safer than mechanical mitral prosthesis in young women[J]. Heart Surg Forum,2020,23(5):E677-E684.
[18] Chu MWA,Ruel M,Graeve A,et al. Low-dose vs standard warfarin after mechanical mitral valve replacement:a randomized trial[J]. Ann Thorac Surg,2023,115(4):929-938.
[19] Kim JS,Kang Y,Sohn SH,et al. Long-term clinical outcomes of the On-X mechanical prosthetic valve in the aortic or mitral position—A single-center experience of up to 20 years’ follow up[J]. Circ J,2021,85(7):1042-1049.
[20] Reyes G,Mu?oz D,Monguio E,et al. Long-term outcomes with the On-X bileaflet mitral valve:clinical events up to 17 years in 661 patients[J]. Eur J Cardiothorac Surg,2022,62(5):ezac157.
[21] Rottenstreich A,Kalish Y,Ta-Shma A,et al. Pregnancy with newer generation aortic On-X mechanical valve[J]. J Obstet Gynaecol,2021,41(6):986-987.
[22] Osman M,Kawsara A,Alkhouli M. National trends in mechanical and bioprosthetic valve replacement among women of childbearing age[J]. Am J Cardiol,2021,146:137-138.
[23] Grashuis P,Khargi SDM,Veen K,et al. Pregnancy outcomes in women with a mitral valve prosthesis:a systematic review and meta-analysis[J]. JTCVS Open,2023,14:102-122.
[24] Marro M,Kossar AP,Xue Y,et al. Noncalcific mechanisms of bioprosthetic structural valve degeneration[J]. J Am Heart Assoc,2021,10(3):e018921.
[25] Whelan A,Williams E,Fitzpatrick E,et al. Collagen fibre-mediated mechanical damage increases calcification of bovine pericardium for use in bioprosthetic heart valves[J]. Acta Biomater,2021,128:384-392.
[26] Wichert-Schmitt B,Grewal J,Malinowski AK,et al. Outcomes of pregnancy in women with bioprosthetic heart valves with or without valve dysfunction[J]. J Am Coll Cardiol,2022,80(21):2014-2024.
[27] Chen CY,Lin CP,Hung KC,et al. Durability of biological valves implanted in aortic or mitral positions:a nationwide cohort study[J]. Ann Thorac Surg,2023,116(4):751-757.
[28] Velho TR,Pereira RM,Fernandes F,et al. Bioprosthetic aortic valve degeneration:a review from a basic science perspective[J]. Braz J Cardiovasc Surg,2022,37(2):239-250.
[29] Percy ED,Harloff M,Hirji S,et al. Subclinical structural valve degeneration in young patients with bioprosthetic aortic valves[J]. Ann Thorac Surg,2021,111(5):1486-1493.
[30] Francica A,Benvegnù L,San Biagio L,et al. Ten-year clinical and echocardiographic follow-up of third-generation biological prostheses in the aortic position[J]. J Thorac Cardiovasc Surg,2022:S0022-5223(22)01142-4.
[31] Squiers JJ,Robinson NB,Audisio K,et al. Structural valve degeneration of bioprosthetic aortic valves:a network meta-analysis[J]. J Thorac Cardiovasc Surg,2023,166(1):52-59.
[32] Montero Cruces L,Carnero Alcázar M,Pérez Camargo D,et al. 5-Year haemodynamic performance of three aortic bioprostheses. A randomized clinical trial[J]. Eur J Cardiothorac Surg,2023,64(2):ezad261.
[33] Beaver T,Bavaria JE,Griffith B,et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis[J]. J Thorac Cardiovasc Surg,2023:S0022-5223(23)00873-5.
[34] Bartus K,Litwinowicz R,Bilewska A,et al. Final 5-year outcomes following aortic valve replacement with a RESILIA? tissue bioprosthesis[J]. Eur J Cardiothorac Surg,2021,59(2):434-441.
[35] Bernard J,Georges G,Hecht S,et al. Mid-term clinical and echocardiographic results of the INSPIRIS RESILIA aortic valve:a retrospective comparison to the Magna Ease[J]. Interdiscip Cardiovasc Thorac Surg,2023,37(1):ivad117.
[36] Ciolacu DE,Nicu R,Ciolacu F. Natural polymers in heart valve tissue engineering:strategies,advances and challenges[J]. Biomedicines,2022,10(5):1095.
[37] Fioretta ES,Motta SE,Lintas V,et al. Next-generation tissue-engineered heart valves with repair,remodelling and regeneration capacity[J]. Nat Rev Cardiol,2021,18(2):92-116.
[38] Cordoves EM,Vunjak-Novakovic G,Kalfa DM. Designing biocompatible tissue engineered heart valves in situ[J]. J Am Coll Cardiol,2023,81(10):994-1003.
[39] Narayan P,Dimagli A,Fudulu DP,et al. Risk factors and outcomes of reoperative surgical aortic valve replacement in the United Kingdom[J]. Ann Thorac Surg,2023,116(4):759-766.
[40] Xu X,Liu H,Gu J,et al. Valve-in-valve/valve-in-ring transcatheter mitral valve implantation vs. redo surgical mitral valve replacement for patients with failed bioprosthetic valves or annuloplasty rings:a systematic review and meta-analysis[J]. Heliyon,2023,9(5):e16078.
[41] van Nieuwkerk AC,Santos RB,Fernandez-Nofrerias E,et al. Outcomes in valve-in-valve transcatheter aortic valve implantation[J]. Am J Cardiol,2022,172:81-89.
[42] Buono A,Maffeo D,Troise G,et al. Trans-catheter valve-in-valve implantation for the treatment of aortic bioprosthetic valve failure[J]. J Clin Med,2022,11(2):344.
[43] Ng AP,Verma A,Sanaiha Y,et al. Maternal and fetal outcomes in pregnant patients with mechanical and bioprosthetic heart valves[J]. J Am Heart Assoc,2023,12(10):e028653.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金地区科学基金项目（82060907）
更新日期/Last Update: 2024-07-26